A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by Cardiopulmonary Exercise Testing in Subjects with World Health Organization Group 1 Pulmonary Hypertension Who Recently Initiated Therapy (ADVANCE Capacity)

• Protocol code: ROR-PH-302
• EudraCT code: 2019-003309-88
• Research group: Pneumology
• Service: Pneumology
• Principal investigator:  López Meseguer, Manuel
• Pathology: Malalties del sistema respiratori
• Phase: Fase III